BioMark is proud to partner and cooperate with National Cancer Institute in Bangladesh and BioMark China in a phase III multi site trial. The trail will involve over 400 subjects and will focus on 4 cancer indications. All the procedures will follow North American regulatory guidelines that were prepared by Saint Boniface Research centre’s regulatory group.
News
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing
June 11, 2026
